英文名稱(chēng) | Apricitabine | SPD754 | AVX754 |
---|---|
中文名稱(chēng) | 阿立他濱 | 阿普瑞西他濱 |
CAS號(hào) | 160707-69-7 |
分子式 | C8H11N3O3S |
分子量 | 229.26 |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
1 mg | 3-5days | ¥886.00 | 登錄后可見(jiàn) | |
5 mg | 3-5days | ¥1766.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Apricitabine | SPD754 | AVX754 |
---|---|
中文名稱(chēng) | 阿立他濱 | 阿普瑞西他濱 |
CAS號(hào) | 160707-69-7 |
分子式 | C8H11N3O3S |
分子量 | 229.26 |
Apricitabine (SPD754) is a highly selective and orally active HIV-1 reverse transcriptase inhibitor (Ki=0.08 μM), the (-) enantiomer of 2′-deoxy-3′-oxy-4′-thiocytidine (dOTC) . Apricitabine inhibits DNA polymerase α, β and γ with Ki values of 300 μM, 12 μM and 112.25 μM, respectively. Apricitabine has shown good antiretroviral therapeutic efficacy in antiretroviral HIV-infected patients, with good tolerability and low selective resistance.
PMID: 10428900 PMCID: PMC89378 DOI: 10.1128/AAC.43.8.1835
PMID: 16816554 DOI: 10.1097/01.aids.0000232233.41877.63